Wednesday, July 8, 2026

Drug profile · INN

naloxegol oxalate

naloxegol oxalate (MOVANTIK) is a mu opioid receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 2
Pipeline programs 0
News articles 0
Drug details — naloxegol oxalate
US status
approved
Class
Route
ORAL
Patents
2
Programs
0
Data quality
0.84

Quick answer

naloxegol oxalate (MOVANTIK) is a mu opioid receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN naloxegol oxalate
Brand MOVANTIK
Mechanism Mu opioid receptor antagonist
Target Mu-type opioid receptor
Route ORAL
Formulation TABLET

Mechanism of action

Mu opioid receptor antagonist

Primary target: Mu-type opioid receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. alvimopan Mu opioid receptor antagonist
  2. loperamide hydrochloride Mu opioid receptor agonist
  3. methadone hydrochloride Mu opioid receptor agonist
  4. morphine sulfate Mu opioid receptor agonist
  5. oxycodone Mu opioid receptor agonist
  6. oxycodone hydrochloride Mu opioid receptor agonist

Related patents

  1. US 9012469

    Crystalline naloxol-peg conjugate

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 7786133

    Chemically modified small molecules

    Expires Mon Aug 26 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is naloxegol oxalate?

naloxegol oxalate (MOVANTIK) is a mu opioid receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for naloxegol oxalate?

MOVANTIK is a marketed brand name for naloxegol oxalate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of naloxegol oxalate?

naloxegol oxalate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.